Our Therapeutic Antibody Discovery Platforms
OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems.
Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes. OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.
Learn about our computationally powered antigen design platform for challenging therapeutic targets.
World-class transgenic animals for the generation of naturally optimized human antibodies® in multiple modalities.
Robust high-throughput screening enables deep searches into immune repertoires to identify unique antibodies with a superior target profile.
Leverage the full suite of OmniAb technologies for enhanced discovery and optimization.
As one of the world’s leaders in antibody engineering & therapeutics, we leverage our technology and expertise to advance discovery and drug development. The state-of-the-art transgenic animal technology we utilize gives our partners access to the most diverse antibody repertoires in the industry, as well as our cutting-edge screening technologies. We are the only company currently operating in this sector that provides multiple transgenic animal species, ranging from rats and mice to chickens and cow-based technologies. The extent of our therapeutic antibody engineering capabilities makes us an ideal partner for research institutions and biopharmaceutical firms around the globe.
We partner closely with you to develop a plan that suits your specific requirements. To learn more about how the depth of our scientific knowledge can be put to work on your next project, reach out and speak with one of our representatives today.
Partnerships with Contract Research Organizations (CROs)
OmniAb works with a comprehensive network of international contract research organizations (CROs) with substantial experience generating OmniAb antibodies and with expertise in characterization, bioinformatics, cell line development, and GMP manufacturing. Current CROs include:
